Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

5.93USD
4:00pm EDT
Change (% chg)

$-0.26 (-4.20%)
Prev Close
$6.19
Open
$6.34
Day's High
$6.34
Day's Low
$5.73
Volume
25,883
Avg. Vol
31,471
52-wk High
$21.59
52-wk Low
$5.55

Latest Key Developments (Source: Significant Developments)

Gemphire Therapeutics Announces Start Of First Nash Proof-Of-Concept Clinical Trial
Thursday, 21 Dec 2017 06:00am EST 

Dec 21 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS ANNOUNCES INITIATION OF ITS FIRST NASH PROOF-OF-CONCEPT CLINICAL TRIAL AND ITS DIFFERENTIATED NASH PROGRAM.GEMPHIRE THERAPEUTICS INC - NASH PROGRAM EXPECTED TO BE PHASE 2B READY BY YEAR-END 2018.GEMPHIRE THERAPEUTICS INC - PLANS TO LAUNCH A SECOND PHASE 2A PROOF-OF-CONCEPT TRIAL IN NASH EARLY IN 2018.  Full Article

Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr
Monday, 13 Nov 2017 09:05am EST 

Nov 13 (Reuters) - Gemphire Therapeutics Inc :Gemphire Therapeutics Inc qtrly loss per share $0.82‍​.  Full Article

Gemphire Therapeutics announces closing of initial public offering
Wednesday, 10 Aug 2016 04:05pm EDT 

Gemphire Therapeutics Inc :Gemphire therapeutics announces closing of initial public offering.  Full Article

Gemphire Therapeutics shares open at $9.25 in debut
Friday, 5 Aug 2016 10:51am EDT 

: Gemphire Therapeutics Inc shares open at $9.25 in debut, below IPO price of $10.00 per share Further company coverage: [GEMP.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Gemphire Therapeutics says public offering of 3 mln shares at $10/shr
Thursday, 4 Aug 2016 05:57pm EDT 

Gemphire Therapeutics Inc : Initial public offering of 3 million shares of its common stock at a price to public of $10.00 per share .Gemphire therapeutics announces pricing of initial public offering.  Full Article

Gemphire Therapeutics sees IPO priced between $11-$13 per share
Monday, 13 Jun 2016 06:45am EDT 

Gemphire Therapeutics Inc :Sees IPO of 3.75 million shares of co's common stock to be priced between $11.00 and $13.00 per share.  Full Article

BRIEF-Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​

* GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS